PSMA ADC: Additional Phase II data

Data from 50 evaluable CRPC patients with progressive disease despite treatment with >=1 taxane-containing chemotherapy in the open-label, U.S. Phase II PSMA ADC 2301 trial showed that IV PSMA ADC given every 3 weeks for up to 8 cycles led to stable disease in 42 patients. The 6-month overall survival (OS) rate was 86%. The trial has enrolled 83 patients. Data were presented at the American Society of Clinical Oncology meeting in Chicago. ...